

# SEPSIS MANAGEMENT – CLINICAL UPDATE

**R. Phillip Dellinger MD, MSc, MCCM  
Professor of Medicine and Distinguished Scholar  
Cooper Medical School of Rowan University  
Director Cooper Research Institute  
Senior Critical Care Attending  
Cooper University Hospital  
Camden NJ USA**

**No Potential Financial COI**



VS



Fluids versus Vasopressors  
for MAP Target

Surviving Sepsis  
Campaign




Sepsis Bundles



VS



## Fluids versus Vasopressors for MAP Target



Dellinger RP. Cardiovascular management of septic shock. *Crit Care Med* 2003;31:946-955.

## Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016

Andrew Rhodes, MB BS, MD(Res) (Co-chair)<sup>1</sup>; Laura E. Evans, MD, MSc, FCCM (Co-chair)<sup>2</sup>; Waleed Alhazzani, MD, MSc, FRCPC (methodology chair)<sup>3</sup>; Mitchell M. Levy, MD, MCCM<sup>4</sup>; Massimo Antonelli, MD<sup>5</sup>; Ricard Ferrer, MD, PhD<sup>6</sup>; Anand Kumar, MD, FCCM<sup>7</sup>; Jonathan E. Sevransky, MD, FCCM<sup>8</sup>; Charles L. Sprung, MD, JD, MCCM<sup>9</sup>; Mark E. Nunnally, MD, FCCM<sup>2</sup>; Bram Rochwerf, MD, MSc (Epi)<sup>3</sup>; Gordon D. Rubinfeld, MD (conflict of interest chair)<sup>10</sup>; Derek C. Angus, MD, MPH, MCCM<sup>11</sup>; Djillali Annane, MD<sup>12</sup>; Richard J. Beale, MD, MB BS<sup>13</sup>; Geoffrey J. Bellinghan, MRCP<sup>14</sup>; Gordon R. Bernard, MD<sup>15</sup>; Jean-Daniel Chiche, MD<sup>16</sup>; Craig Coopersmith, MD, FACS, FCCM<sup>8</sup>; Daniel P. De Backer, MD, PhD<sup>17</sup>; Craig J. French, MB BS<sup>18</sup>; Seitaro Fujishima, MD<sup>19</sup>; Herwig Gerlach, MBA, MD, PhD<sup>20</sup>; Jorge Luis Hidalgo, MD, MACP, MCCM<sup>21</sup>; Steven M. Hollenberg, MD, FCCM<sup>22</sup>; Alan E. Jones, MD<sup>23</sup>; Dilip R. Karnad, MD, FACP<sup>24</sup>; Ruth M. Kleinpell, PhD, RN-CS, FCCM<sup>25</sup>; Younsuk Koh, MD, PhD, FCCM<sup>26</sup>; Thiago Costa Lisboa, MD<sup>27</sup>; Flavia R. Machado, MD, PhD<sup>28</sup>; John J. Marini, MD<sup>29</sup>; John C. Marshall, MD, FRCSC<sup>30</sup>; John E. Mazuski, MD, PhD, FCCM<sup>31</sup>; Lauralyn A. McIntyre, MD, MSc, FRCPC<sup>32</sup>; Anthony S. McLean, MB ChB, MD, FRACP, FJFICM<sup>33</sup>; Sangeeta Mehta, MD<sup>34</sup>; Rui P. Moreno, MD, PhD<sup>35</sup>; John Myburgh, MB ChB, MD, PhD, FANZCA, FCICM, FAICD<sup>36</sup>; Paolo Navalesi, MD<sup>37</sup>; Osamu Nishida, MD, PhD<sup>38</sup>; Tiffany M. Osborn, MD, MPH, FCCM<sup>31</sup>; Anders Perner, MD<sup>39</sup>; Colleen M. Plunkett<sup>25</sup>; Marco Ranieri, MD<sup>40</sup>; Christa A. Schorr, MSN, RN, FCCM<sup>22</sup>; Maureen A. Seckel, CCRN, CNS, MSN, FCCM<sup>41</sup>; Christopher W. Seymour, MD<sup>42</sup>; Lisa Shieh, MD, PhD<sup>43</sup>; Khalid A. Shukri, MD<sup>44</sup>; Steven Q. Simpson, MD<sup>45</sup>; Mervyn Singer, MD<sup>46</sup>; B. Taylor Thompson, MD<sup>47</sup>; Sean R. Townsend, MD<sup>48</sup>; Thomas Van der Poll, MD<sup>49</sup>; Jean-Louis Vincent, MD, PhD, FCCM<sup>50</sup>; W. Joost Wiersinga, MD, PhD<sup>51</sup>; Janice L. Zimmerman, MD, MACP, MCCM<sup>52</sup>; R. Phillip Dellinger, MD, MCCM<sup>22</sup>

<sup>1</sup>St. George's Hospital London, England, United Kingdom.

<sup>2</sup>New York University School of Medicine New York, NY.

<sup>3</sup>McMaster University Hamilton, Ontario, Canada.

<sup>4</sup>Brown University School of Medicine Providence, RI.

<sup>5</sup>Istituto di Anestesiologia e Rianimazione, Università Cattolica del Sacro Cuore, Rome, Italy.

<sup>6</sup>Vall d'Hebron University Hospital Barcelona, Spain.

<sup>7</sup>University of Manitoba Winnipeg, Manitoba, Canada.

<sup>8</sup>Emory University Hospital Atlanta, GA.

Copyright © 2017 by the Society of Critical Care Medicine and the European Society of Intensive Care Medicine

DOI: 10.1097/CCM.0000000000002255

<sup>9</sup>Hadassah Hebrew University Medical Center Jerusalem, Israel.

<sup>10</sup>Sunnybrook Health Sciences Centre Toronto, Ontario, Canada.

<sup>11</sup>University of Pittsburgh Critical Care Medicine CRISMA Laboratory Pittsburgh, PA.

<sup>12</sup>Hospital Raymond Poincare Garches, France.

<sup>13</sup>Saint Thomas Hospital London, England, United Kingdom.

<sup>14</sup>University College London Hospitals London, England, United Kingdom.

<sup>15</sup>Vanderbilt University Medical Center Nashville, TN.

<sup>16</sup>Service de Réanimation Médicale Paris, France.


<sup>17</sup>CHIREC Hospitals Braine L'Alleud, Belgium.

<sup>18</sup>Western Hospital Victoria, Australia.

<sup>19</sup>Keio University School of Medicine, Tokyo, Japan.



Crit Care Med 2017  
Mar,45(3): 486-552



**30 ml/kg crystalloid first 3 hrs**

SEPSIS BUNDLE PROJECT (SEP)  
NATIONAL HOSPITAL INPATIENT QUALITY  
MEASURES

SEP-1 EARLY MANAGEMENT BUNDLE,  
SEVERE SEPSIS/SEPTIC SHOCK

---





ORIGINAL ARTICLE

## A Randomized Trial of Protocol-Based Care for Early Septic Shock

The ProCESS Investigators\*

**N Engl J Med. 2014 May 1;370(18):1683-93.**

**Over 1500 Patients**

ORIGINAL ARTICLE


## Goal-Directed Resuscitation for Patients with Early Septic Shock

The ARISE Investigators and the ANZICS Clinical Trials Group\*

**N Engl J Med. 2014 Oct 16;371(16):1496-506.**

**1600 Patients**


**18.2-21.0 %  
Mortality**



## **End Stage Renal Disease on Dialysis**



## **Compensated Congestive Heart failure**



Dellinger RP. Cardiovascular management of septic shock. *Crit Care Med* 2003;31:946-955.



# SEPTIC SHOCK


- **Recommend MAP  $\geq 65$  mm Hg**




# Mean Arterial Pressure

	65 mm Hg	75 mm Hg	85 mm Hg	F/LT
Urinary output (mL)	49 $\pm$ 18	56 $\pm$ 21	43 $\pm$ 13	.60/.71
Capillary blood flow (mL/min/100 g)	6.0 $\pm$ 1.6	5.8 $\pm$ 1.1	5.3 $\pm$ 0.9	.59/.55
Red Cell Velocity (au)	0.42 $\pm$ 0.06	0.44 $\pm$ 0.016	0.42 $\pm$ 0.06	.74/.97
Pico <sub>2</sub> (mm Hg)	41 $\pm$ 2	47 $\pm$ 2	46 $\pm$ 2	.11/.12
Pa-Pico <sub>2</sub> (mm Hg)	13 $\pm$ 3	17 $\pm$ 3	16 $\pm$ 3	.27/.40

Adapted from Table 4, page 2731, from LeDoux, Astiz ME, Carpati CM, Rackow ED. Effects of perfusion pressure on tissue perfusion in septic shock. *Crit Care Med* 2000; 28:2729-2732



Asfar P, et al. N Engl J Med. 2014 Apr  
24;370(17):1583-93.  
**776 Patients**




Asfar P, et al. N Engl J Med. 2014 Apr 24;370(17):1583-93.




# CHOICE OF VASOPRESSOR

## During Septic Shock

**End  
Diastole**




**End  
Systole**




## 10 Days Post Shock

**End  
Diastole**



**End  
Systole**



# VASOPRESSORS IN SEPTIC SHOCK

First  
Line

**Norepinephrine**

```
graph TD; Norepinephrine --> Epinephrine; Norepinephrine --> Vasopressin;
```

Second  
Line

**Epinephrine**

**Low Dose  
Vasopressin**  
(.01-.03 units/min)

---

Niche  
Drugs

**Dopamine**  
(sinus  
bradycardia)

**Phenylephrine**  
(high cardiac output  
or serious  
tachyarrhythmias  
and salvage)

*The* NEW ENGLAND  
JOURNAL *of* MEDICINE

ESTABLISHED IN 1812

AUGUST 3, 2017



VOL. 377 NO. 5

Angiotensin II for the Treatment of Vasodilatory Shock


Ashish Khanna, M.D., Shane W. English, M.D., Xueyuan S. Wang, M.D., Kealy Ham, M.D., James Tumlin, M.D., Harold Szerlip, M.D., Laurence W. Busse, M.D., Laith Altaweel, M.D., Timothy E. Albertson, M.D., M.P.H., Ph.D., Caleb Mackey, M.D., Michael T. McCurdy, M.D., David W. Boldt, M.D., Stefan Chock, M.D., Paul J. Young, M.B., Ch.B., Ph.D., Kenneth Krell, M.D., Richard G. Wunderink, M.D., Marlies Ostermann, M.D., Ph.D., Raghavan Murugan, M.D., Michelle N. Gong, M.D., Rakshit Panwar, M.D., Johanna Hästbacka, M.D., Ph.D., Raphael Favory, M.D., Ph.D., Balasubramanian Venkatesh, M.D., B. Taylor Thompson, M.D., Rinaldo Bellomo, M.D., Jeffrey Jensen, B.S., Stew Kroll, M.A., Lakhmir S. Chawla, M.D., George F. Tidmarsh, M.D., Ph.D., and Adam M. Deane, M.D., for the ATHOS-3 Investigators\*

# Controversy


- How much fluid after the initial bolus?




# Interstitial Edema



Lungs



Brain



Kidney



# De-resuscitation





Arterial Pressure = Flow x Resistance

Arterial Pressure Drives Tissue Perfusion and is Determined by Cardiac Output and Systemic Systemic Vascular Resistance



Assume continued leak and MAP target 70 mm Hg



Download from  
**Dreamstime.com**

This watermark-free image is for previewing purposes only.



40924116

Arts9vector | Dreamstime.com

ARTICLE IN PRESS


[ Original Research ]

 CHEST

# Impact of Vasoactive Medications on ICU-Acquired Weakness in Mechanically Ventilated Patients

*Krysta S. Wolfe, MD; Bhakti K. Patel, MD; Erica L. MacKenzie, MD; Shewit P. Giovanni, MD; Anne S. Pohlman, MSN;  
Matthew M. Churpek, MD, MPH, PhD; Jesse B. Hall, MD; and John P. Kress, MD*

Figure 1



Wolfe, KS. et al. Chest 2018



Correct balance of fluids and  
vasopressors is the goal

LES PETITS FAIRYTALES

# Goldilocks and the Three Bears



**Trixie Belle and  
Melissa Caruso-Scott**

**illustrated by  
Oliver Lake**



# Goldilocks



Not enough



Too Much



Just Right



Correct balance of fluids and  
vasopressors is the goal

**We just aren't sure what it is for any given patient.**

Crystalloid Liberal or Vasopressors Early  
Resuscitation of Sepsis Trial  
**CLOVERS Trial**

**National Heart Lung Blood Institute**

Prevention and Early Treatment of Acute  
Lung Injury Network  
**PETAL Network**



1600 20th Street, NW • Washington, D.C. 20009 • 202/588-1000 • [www.citizen.org](http://www.citizen.org)

August 28, 2018

Jerry Menikoff, M.D., J.D.  
Director  
Office for Human Research Protections  
U.S. Department of Health and Human Services  
1101 Wootton Parkway, Suite 200  
Rockville, MD 20852

**Re: Project Title: Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis Trial**  
**Sponsor: National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health**  
**Principal Investigator: David A. Schoenfeld, Ph.D., Massachusetts General Hospital, Clinical Coordination Center for the NHLBI-funded Clinical Trials Network for the Prevention and Early Treatment of Acute Lung Injury (PETAL Network)**  
**ClinicalTrials.gov Identifier: NCT03434028**

Dear Dr. Menikoff:

Public Citizen, a consumer advocacy organization with more than 500,000 members and supporters nationwide, hereby requests that the Office for Human Research Protections (OHRP) immediately direct NHLBI to terminate enrollment in the Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis trial (CLOVERS) and launch a compliance oversight investigation of the trial and its review and approval by the responsible institutional review board(s) (IRBs).

Surviving Sepsis  
Campaign



Sepsis Bundles

# GUIDELINES TO BUNDLES - 2004

## Special Articles

### Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock

R. Phillip Dellinger, MD; Jean M. Carlet, MD; Henry Masur, MD; Herwig Gerlach, MD, PhD; Thierry Calandra, MD; Jonathan Cohen, MD; Juan Gea-Banacloche, MD, PhD; Didier Keh, MD; John C. Marshall, MD; Margaret M. Parker, MD; Graham Ramsay, MD; Janice L. Zimmerman, MD; Jean-Louis Vincent, MD, PhD; Mitchell M. Levy, MD; for the Surviving Sepsis Campaign Management Guidelines Committee

Sponsoring Organizations: American Association of Critical-Care Nurses, American College of Chest Physicians, American College of Emergency Physicians, American Thoracic Society, Australian and New Zealand Intensive Care Society, European Society of Clinical Microbiology and Infectious Diseases, European Society of Intensive Care Medicine, European Respiratory Society, International Sepsis Forum, Society of Critical Care Medicine, Surgical Infection Society.

**Objective:** In 2003, critical care and infectious disease experts representing 11 international organizations developed management guidelines for severe sepsis and septic shock that would be practical use for the bedside clinician, under the auspices of the Surviving Sepsis Campaign, an international effort to increase awareness and improve outcome in severe sepsis.

**Design:** The process included a modified Delphi method, a consensus conference, several subsequent smaller meetings of sub-groups and key individuals, teleconferences, and electronic-based discussion among subgroups and among the entire committee.

**Methods:** We used a modified Delphi methodology for grading recommendations, built on a 2001 publication sponsored by the International Sepsis Forum. We undertook a systematic review of the literature graded along five levels to create recommendation grades from A to E, with A being the highest grade. Pediatric considerations were provided to contrast adult and pediatric management.

**Results:** Key recommendations, listed by category and not by hierarchy, include early goal-directed resuscitation of the septic patient during the first 6 hrs after recognition; appropriate diagnostic studies to ascertain causative organisms before starting antibiotics; early administration of broad-spectrum antibiotic therapy; reassessment of antibiotic therapy with microbiology and clinical data to narrow coverage, when appropriate; a usual 7-10 days of antibiotic therapy guided by clinical response; source control with attention to the method that balances risks and benefits; equivalence of crystalloid and colloid resuscitation; aggressive fluid challenge to restore mean circulating filling pressure; vasopressor preference for norepinephrine and dopamine; cautious use of vasopressin pending further studies; avoiding low-dose dopamine administration for renal protection; consideration of dobutamine inotropic therapy in some clinical situations; avoidance of supranormal oxygen delivery as a goal of therapy; stress-dose steroid therapy for septic shock; use of recombinant activated protein C in patients with severe sepsis and high risk

for death; with resolution of tissue hypoperfusion and in the absence of coronary artery disease or acute hemorrhage, targeting a hemoglobin of 7-9 g/dL; appropriate use of fresh frozen plasma and platelets; a low tidal volume and limitation of inspiratory plateau pressure strategy for acute lung injury and acute respiratory distress syndrome; application of a minimal amount of positive end-expiratory pressure in acute lung injury/acute respiratory distress syndrome; a semirecumbent bed position unless contraindicated; protocols for weaning and sedation/analgesia, using either intermittent bolus sedation or continuous infusion sedation with daily interruptions/lightening; avoidance of neuromuscular blockers, if at all possible; maintenance of blood glucose <150 mg/dL after initial stabilization; equivalence of continuous veno-veno hemofiltration and intermittent hemodialysis; lack of utility of bicarbonate use for pH  $\geq$  7.35; use of deep vein thrombosis/stress ulcer prophylaxis; and consideration of limitation of support where appropriate. Pediatric considerations included a more likely need for intubation due to low functional residual capacity; more difficult intravenous access; fluid resuscitation based on weight with 40-60 mL/kg or higher needed; decreased cardiac output and increased systemic vascular resistance as the most common hemodynamic profile; greater use of physical examination therapeutic end points; unsettled issue of high-dose steroids for therapy of septic shock; and greater risk of hypoglycemia with aggressive glucose control.

**Conclusion:** Evidence-based recommendations can be made regarding many aspects of the acute management of sepsis and septic shock that are hoped to translate into improved outcomes for the critically ill patient. The impact of these guidelines will be formally tested and guidelines updated annually and even more rapidly as some important new knowledge becomes available. (Crit Care Med 2004; 32:858-873)

**Key Words:** sepsis; severe sepsis; septic shock; sepsis syndrome; infection; guidelines; evidence-based medicine; Surviving Sepsis Campaign

Copyright © 2004 by the Society of Critical Care Medicine  
DOI: 10.1097/01.CCM.0000117317.1.8002.E4

## Severe Sepsis Bundles:

### Sepsis Resuscitation Bundle

(To be accomplished as soon as possible and scored over first 6 hours):

1. Serum lactate measured.
2. Blood cultures obtained prior to antibiotic administration.
3. From the time of presentation, broad-spectrum antibiotics administered within 3 hours for ED admissions and 1 hour for non-ED ICU admissions.
4. In the event of hypotension and/or lactate  $>$  4 mmol/L (36 mg/dl):
  - a) Deliver an initial minimum of 20 mL/kg of crystalloid (or colloid equivalent\*).
  - b) Apply vasopressors for hypotension not responding to initial fluid resuscitation to maintain mean arterial pressure (MAP)  $\geq$  65 mm Hg.
5. In the event of persistent hypotension despite fluid resuscitation (septic shock) and/or lactate  $>$  4 mmol/L (36 mg/dl):
  - a) Achieve central venous pressure (CVP) of  $\geq$  8 mm Hg.
  - b) Achieve central venous oxygen saturation (ScvO<sub>2</sub>) of  $\geq$  70%. \*\*

### Sepsis Management Bundle

(To be accomplished as soon as possible and scored over first 24 hours):

1. Low-dose steroids\* administered for septic shock in accordance with a standardized ICU policy.
2. Drotrecogin alfa (activated) administered in accordance with a standardized ICU policy.
3. Glucose control maintained  $\geq$  lower limit of normal, but  $<$  150 mg/dl (8.3 mmol/L).
4. Inspiratory plateau pressures maintained  $<$  30 cm H<sub>2</sub>O for mechanically ventilated patients.

\*See the individual chart measurement tool for an equivalency chart.

\*\*Achieving a mixed venous oxygen saturation (SvO<sub>2</sub>) of 65% is an acceptable alternative.

6 hour

24 hour

# **SURVIVING SEPSIS CAMPAIGN: INTERNATIONAL GUIDELINES FOR MANAGEMENT OF SEVERE SEPSIS AND SEPTIC SHOCK 2012**

**R. Phillip Dellinger, Mitchell M. Levy, Andrew Rhodes, Djillali Annane, Herwig Gerlach, Steven M. Opal, Jonathan E. Sevransky, Charles L. Sprung, Ivor S. Douglas, Roman Jaeschke, Tiffany M. Osborn, Mark E. Nunnally, Sean R. Townsend, Konrad Reinhart, Ruth M. Kleinpell, Derek C. Angus, Clifford S. Deutschman, Flavia R. Machado, Gordon D. Rubenfeld, Steven A. Webb, Richard J. Beale, Jean-Louis Vincent, Rui Moreno, and the Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup.**

**Crit Care Med 2013; 41:580-637  
Intensive Care Medicine 2013; 39: 165-228**

**Surviving Sepsis  
Campaign**

The logo for the Surviving Sepsis Campaign features the text "Surviving Sepsis" in a light green font and "Campaign" in a blue font. To the right of the text are several blue dots of varying sizes, arranged in a pattern that suggests a globe or a network.

# 2012 Surviving Sepsis Campaign Guidelines

## Two Clocks





# 2012 SEPSIS BUNDLES

## **TO BE COMPLETED WITHIN 3 HOURS OF TIME OF PRESENTATION :**

1. Measure lactate level
2. Obtain blood cultures prior to administration of antibiotics
3. Administer broad spectrum antibiotics
4. Administer 30ml/kg crystalloid for hypotension or lactate  $\geq 4$ mmol/L

## **TO BE COMPLETED WITHIN 6 HOURS OF TIME OF PRESENTATION:**

5. Apply vasopressors (for hypotension that does not respond to initial fluid resuscitation to maintain a mean arterial pressure (MAP)  $\geq 65$ mmHg)
6. In the event of persistent arterial hypotension despite volume resuscitation (septic shock) or initial lactate  $\geq 4$  mmol/L (36mg/dl):
  - Measure central venous pressure (CVP)
  - Measure central venous oxygen saturation (ScvO<sub>2</sub>)
7. Remeasure lactate if elevated.

ORIGINAL ARTICLE

## A Randomized Trial of Protocol-Based Care for Early Septic Shock

The ProCESS Investigators\*

**N Engl J Med. 2014 May 1;370(18):1683-93.**

**Over 1500 Patients**

ORIGINAL ARTICLE

## Goal-Directed Resuscitation for Patients with Early Septic Shock

The ARISE Investigators and the ANZICS Clinical Trials Group\*

**N Engl J Med. 2014 Oct 16;371(16):1496-506.**

**1600 Patients**

SEPSIS BUNDLE PROJECT (SEP)  
NATIONAL HOSPITAL INPATIENT QUALITY  
MEASURES

SEP-1 EARLY MANAGEMENT BUNDLE,  
SEVERE SEPSIS/SEPTIC SHOCK

---



# SEPTIC SHOCK

## Reassessment after 30 ml/kg fluid Rx

6 hr.



**Persistent Hypotension  
OR Lactate > 4**

- Reassessment after 30 ml/kg crystalloid

### Shock Assessment

---

#### Physical Exam (ALL)

- Vital Signs (T, HR, RR, BP)
- Cardiopulmonary exam
- Capillary refill evaluation
- Peripheral Pulse evaluation
- Skin evaluation

**OR**

#### Hemodynamics (2 of 4)

- CVP
- SVO<sub>2</sub>
- Bedside cardiovascular ultrasound
- Passive leg raise / fluid challenge

# Sepsis Bundles

Surviving Sepsis  
Campaign

**BUNDLES**

## TO BE COMPLETED WITHIN 3 HOURS:

- 1) Measure lactate level.
- 2) Obtain blood cultures prior to administration of antibiotics.
- 3) Administer broad spectrum antibiotics.
- 4) Administer 30 ml/kg crystalloid for hypotension or lactate  $\geq 4$  mmol/L.

“Time of presentation” is defined as the time of triage in the emergency department or, if presenting from another care venue, from the earliest chart annotation consistent with all elements of severe sepsis or septic shock ascertained through chart review.

## TO BE COMPLETED WITHIN 6 HOURS:

- 5) Apply vasopressors (for hypotension that does not respond to initial fluid resuscitation) to maintain a mean arterial pressure (MAP)  $\geq 65$  mm Hg.
- 6) In the event of persistent hypotension after initial fluid administration (MAP  $< 65$  mm Hg) or if initial lactate was  $\geq 4$  mmol/L, re-assess volume status and tissue perfusion and document findings according to Table 1.
7. Re-measure lactate if initial lactate elevated.



# Surviving Sepsis Campaign

## Three Clocks



# Hour-1 Bundle

- The objective of the “hour-1” bundle is to *begin* resuscitation and management immediately.
- Although some of the resuscitation measures may require more than an hour to complete, the focus is to *begin* treatment immediately.



# Hour-1 Bundle- 5 Key Elements

1. Measure lactate level. (To be remeasured if initial lactate is  $>2$  mmol/L).
2. Obtain blood cultures prior to administration of antibiotics.
3. Administer broad-spectrum antibiotics.
4. Begin rapid administration of 30ml/kg crystalloid fluids for hypotension or lactate  $\geq 4$  mmol/L.
5. Apply vasopressors if the patient is hypotensive during or after fluid resuscitation to maintain mean arterial pressure (MAP)  $\geq 65$  mm Hg.



# Surviving Sepsis Campaign

## Three Clocks



## SCCM News

### **SCCM and ACEP Release Joint Statement About the Surviving Sepsis Campaign Hour-1 Bundle**

The Society of Critical Care Medicine (SCCM) and the American College of Emergency Physicians (ACEP) acknowledge concerns expressed about the recently released [Surviving Sepsis](#)



[Campaign \(SSC\) hour-1 bundle](#) and the appropriateness of implementation in the United States. Both organizations understand the importance of prompt and optimal sepsis diagnosis and treatment. SCCM and ACEP, along with other involved international experts, are organizing a meeting as soon as possible to carefully review the recommendations and provide guidance on bundle implementation and care of potentially septic patients who present to U.S. emergency departments. SCCM recommends that hospitals not implement the hour-1 bundle in its present form in the United States at this time.

# THE BOTTOM LINE



# TO SAVE LIVES.....



**Early** identification



**Early** antibiotics



**Early** appropriate fluid resuscitation

**THANK YOU**